Genomic Heterogeneity and Copy Number Variant Burden Are Associated with Poor Recurrence-free Survival and 11q Loss in Human Papillomavirus-positive Squamous Cell Carcinoma of the Oropharynx
Overview
Authors
Affiliations
Background: Human papillomavirus-positive (HPV+) squamous cell carcinoma of the oropharynx (OPSCC) is the most prevalent HPV-associated malignancy in the United States. Favorable treatment outcomes have led to increased interest in treatment de-escalation to reduce treatment morbidity as well as the development of prognostic markers to identify appropriately low-risk patients. Intratumoral genomic heterogeneity and copy number alteration burden have been demonstrated to be predictive of poor outcomes in many other cancers; therefore, we sought to determine whether intratumor heterogeneity and genomic instability are associated with poor outcomes in HPV+ OPSCC.
Methods: Tumor heterogeneity estimates were made based on targeted exome sequencing of 45 patients with HPV+ OPSCC tumors. Analysis of an additional cohort of HPV+ OPSCC tumors lacking matched normal sequencing allowed copy number analysis of 99 patient tumors.
Results: High intratumorally genomic heterogeneity and high numbers of copy number alterations were strongly associated with worse recurrence-free survival. Tumors with higher heterogeneity and frequent copy number alterations were associated with loss of distal 11q, which encodes key genes related to double-strand break repair, including ATM and MRE11A.
Conclusions: Both intratumor genomic heterogeneity and high-burden copy number alterations are strongly associated with poor recurrence-free survival in patients with HPV+ OPSCC. The drivers of genomic instability and heterogeneity in these tumors remains to be elucidated. However, 11q loss and defective DNA double-strand break repair have been associated with genomic instability in other solid tumors. Copy number alteration burden and intratumoral heterogeneity represent promising avenues for risk stratification of patients with HPV+OPSCC.
Goswami M, Schlom J, Donahue R Oncotarget. 2024; 14:758-774.
PMID: 38958745 PMC: 11221564. DOI: 10.18632/oncotarget.28487.
Danko B, Hess J, Unger K, Samaga D, Walz C, Walch A NPJ Precis Oncol. 2024; 8(1):116.
PMID: 38783045 PMC: 11116554. DOI: 10.1038/s41698-024-00602-0.
Li J, Li S, Shu M, Hu W J Cell Mol Med. 2024; 28(3):e18108.
PMID: 38279519 PMC: 10844683. DOI: 10.1111/jcmm.18108.
Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Brandt A, Thiele B, Schultheiss C, Daetwyler E, Binder M Cancers (Basel). 2023; 15(7).
PMID: 37046721 PMC: 10093741. DOI: 10.3390/cancers15072051.
Schrank T, Kim S, Rehmani H, Kothari A, Wu D, Yarbrough W Cancers (Basel). 2022; 14(18).
PMID: 36139648 PMC: 9496734. DOI: 10.3390/cancers14184488.